Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
LifeMine Therapeutics
About
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $70M
- Industries
- Biotechnology,Genetics,Life Science,Therapeutics
- Founded date
- Jan 1, 2016
- Number Of Employee
- 101 - 250
- Operating Status
- Active
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development.Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 23, 2022 | Series C | $175M | 1 | — | — | Detail |
| Jan 7, 2021 | Series B | $50M | 1 | — | — | Detail |
| Sep 18, 2017 | Series A | $70M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series C |
Merck
|
— | Series A |
